Oct. 02, 2025 -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to announce the publication of a preclinical study, in a research article entitled “Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leuk

Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, including two doses that are lower than those currently available in single pill combinations, designed to deliver the blood pressure-lowering benefits of triple combination therapy early in the treatment pathway, with an established safety profile George Medicines receives upfront licensing fee and is eligible for regulatory and commercial milestone payments, as well as a fut

Oct. 01, 2025 -- RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneering developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development for early detection and treatment of eye and systemic diseases, and RGEN Inc., a leader in genetic research and innovation (“RGEN”), today announced a strategic partnership to deliver game-changing advancements in the early detection and risk prediction of Advan

Sept. 30, 2025 -- Fifty 1 Labs Inc. (OTC: FITY), a leader in AI-powered healthcare and biotechnology solutions, is excited to announce the signing of a Letter of Intent (LOI) to acquire BioSpark AI Technologies Inc., a Vancouver-based innovator specializing in patented artificial intelligence systems for clinical data extraction, structuring, and real-time analysis. This strategic move builds on a successful history of collaboration between the two companies, reinforcing Fifty 1 Labs' commitme

September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48 per Share, in cash, without interest and subject to any applicable withholding. Such offer is being made upon the terms an

September 26, 2025, 7:00 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), Inserm Transfert (on behalf of Inserm, a French public organization dedicated to human health), and Nantes University today announce the signing of a strategic partnership agreement aimed at accelerating the development of innovative projects in the fields of immunotherapy for oncology, inflammation, and autoimmunity. By combining academic research with industrial expertise, the partnership seeks to tran

Sept. 26, 2025 -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an agreement to acquire Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. The closing of this acquisition is subject to customary closing conditions, including approval by Melt stockholders,

Numab to receive first milestone payment Boehringer Ingelheim has advanced its novel tumor antigen targeting T cell engager resulting from a collaboration with Numab into preclinical development Sept. 25, 2025 -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, announced today that Boehringer Ingelheim has advanced its novel T cell engager for the treatment of lung and gastrointestinal (GI) cancer

Sept. 25, 2025 -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has signed a distribution agreement with Veridion Group (“Veridion”) of New Zealand, to act as exclusive distribution agent for its LaNeo MDMA in the Netherlands market. “With the approval of the first Authorized Prescriber

Sept. 24, 2025 -- Cellectar Biosciences, Inc. (“Cellectar”) (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Evestia Clinical (“Evestia”), a leading independent global specialist Contract Research Organization (CRO), have entered into an agreement whereby Evestia will provide Cellectar with full CRO services for their upcoming Phase 1b study evaluating CLR 125 for the treatment of triple-negative b